David Badawi Sells 5,423 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 5,423 shares of the business’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $2.78, for a total value of $15,075.94. Following the completion of the transaction, the chief technology officer now directly owns 1,744,118 shares of the company’s stock, valued at approximately $4,848,648.04. The trade was a 0.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

David Badawi also recently made the following trade(s):

• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The shares were sold at an average price of $3.26, for a total value of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The shares were sold at an average price of $3.52, for a total value of $10,950.72.

Sight Sciences Trading Up 2.8 %

Shares of NASDAQ:SGHT opened at $2.96 on Friday. The company’s 50-day moving average price is $3.55 and its two-hundred day moving average price is $5.32. Sight Sciences, Inc. has a one year low of $2.67 and a one year high of $8.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The stock has a market capitalization of $150.23 million, a PE ratio of -2.90 and a beta of 2.57.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The business had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. On average, equities analysts forecast that Sight Sciences, Inc. will post -1.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on SGHT shares. Lake Street Capital cut their price target on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a research note on Wednesday, January 15th. Piper Sandler reaffirmed a “neutral” rating and issued a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Citigroup lowered their target price on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a report on Wednesday, December 11th. UBS Group assumed coverage on Sight Sciences in a report on Friday, December 6th. They issued a “buy” rating and a $5.50 price target on the stock. Finally, Morgan Stanley decreased their price objective on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Sight Sciences presently has a consensus rating of “Hold” and a consensus price target of $4.72.

Institutional Investors Weigh In On Sight Sciences

Several large investors have recently made changes to their positions in the stock. Rhumbline Advisers raised its position in Sight Sciences by 40.1% during the second quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock worth $272,000 after acquiring an additional 11,671 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Sight Sciences by 31.1% during the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock worth $240,000 after purchasing an additional 8,527 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Sight Sciences in the 2nd quarter valued at about $95,000. Long Focus Capital Management LLC lifted its stake in Sight Sciences by 86.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock valued at $3,739,000 after purchasing an additional 260,594 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. bought a new position in Sight Sciences during the second quarter worth about $1,234,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.